New obesity drug BMF-650 enters first human safety trial
NCT ID NCT07223216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests the safety and tolerability of a new drug called BMF-650 in 80 otherwise healthy adults who are overweight or obese. Participants receive either the drug or a placebo, and researchers monitor for side effects, vital signs, and how the drug moves through the body. The goal is to see if BMF-650 is safe enough to study further for weight control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BMF-650
- What this could lead to
- If successful, this could lead to a new medication for weight management in people with obesity.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not weight loss. The drug may not prove effective or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medpace Clinical Pharmacology
Cincinnati, Ohio, 45227, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?